Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof, wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; R.sup.1a is an optionally substituted aryl or heteroaryl group; R.sup.1b is hydrogen or a group R1a; X is an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 are heteroatoms selected from O, N and S; and A, E, R.sup.2, R.sup.3, R.sup.4, Q.sup.1 and Q.sup.2 are as defined in the claims; provided that when E is aryl or heteroaryl, then Q.sup.2 is other than a bond; and further provided that the moiety (a) is other than a group (BG1) or (BG2); wherein (BG1) and (BG2) are each optionally substituted; T is N or CR.sup.Z; J.sup.1-J.sup.2 is selected from N.dbd.C(R.sup.Z), (R.sup.Z)C.dbd.N, (R.sup.Z)N--C(O), (R.sup.Z).sub.2C--C(O), N.dbd.N and (R.sup.Z)C.dbd.C(R.sup.6); J.sup.4-J.sup.3 is a group N.dbd.C(R.sup.Z) or a group (R.sup.Z)N--CO; and R.sup.Z is hydrogen or a substituent. The compounds of the formula (I) have PKA and PKB kinase inhibiting activity and are useful in the treatment of cancers. ##STR00001##